安捷凯在线客服
- 客服:
- 电话: 13061953619
- 微信:
Ubrogepant (MK-1602) (MK-1602) 是一种新型口服降钙素基因相关肽受体 (CGRP) 拮抗剂,正在开发用于急性偏头痛的治疗。
Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1].
[1]. Li CC, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021.
动态评分
0.0